Search Result
Results for "
PRMTs
" in MedChemExpress (MCE) Product Catalog:
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-162003A
-
|
Histone Methyltransferase
|
Cancer
|
DCPT1061 hydrochloride has a strong inhibitory effect on PRMT1, PRMT6, and PRMT8 in vitro, The epigenetic enzymes such as PRMT3, PRMT4 and PRMT5 had little inhibitory effect. DCPT1061 hydrochloride has antitumor effects .
|
-
-
- HY-18962A
-
|
Histone Methyltransferase
|
Cancer
|
AMI-1 free acid is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC50s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 free acid exerts PRMTs inhibitory effects by blocking peptide-substrate binding .
|
-
-
- HY-155154
-
|
Others
|
Cancer
|
PRMT4-IN-2 (compound 55) is a pan-inhibitor of protein arginine methyltransferase (PRMT) with IC50s of 92 nM (PRMT4), 436 nM (PRMT6), 460 nM (PRMT1), 823 nM ( PRMT8), 1.386 μM (PRMT3) .
|
-
-
- HY-155154A
-
|
Histone Methyltransferase
|
Cancer
|
PRMT4-IN-3 (compound 56) is a potent inhibitor of class I protein arginine methyltransferase (PRMT), targeting PRMT4 (IC50: 37 nM) and PRMT4 (IC50: 253 nM) .
|
-
-
- HY-18962
-
|
Histone Methyltransferase
|
Cancer
|
AMI-1 is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC50s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 exerts PRMTs inhibitory effects by blocking peptide-substrate binding .
|
-
-
- HY-148674
-
-
-
- HY-115758
-
-
-
- HY-162003
-
|
Histone Methyltransferase
|
Cancer
|
DCPT1061 potently inhibits PRMT1, PRMT6 and PRMT8 in vitro with less inhibitory effect on PRMT3, PRMT4, and PRMT5 or other epigenetic enzymes. DCPT1061 has antitumor effect .
|
-
-
- HY-160029
-
-
-
- HY-146810
-
-
-
- HY-Q36691
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-30 (compound 17) is a potent and selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.33 μM and a Kd of 0.987 μM. PRMT5-IN-30 exhibits a broad selectivity against a panel of other methyltransferases. PRMT5-IN-30 inhibits PRMT5 mediated SmD3 methylation .
|
-
-
- HY-155050
-
|
Apoptosis
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-31 (Compound 3m) is a selective PRMT5 inhibitor (IC50: 0.31 μM). PRMT5-IN-31 up-regulates hnRNP E1 protein level. PRMT5-IN-31 occupies the substrate site of PRMT5 and forms essential interactions with amino acid residues. PRMT5-IN-31 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. PRMT5-IN-31 has high metabolic stability on human liver microsomes (T1/2: 132.4 min) .
|
-
-
- HY-153422
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-29 is a potent and orally active PRMT5 Inhibitor with an IC50 of 1.5 μΜ. PRMT5-IN-29 has the potential for advanced cancers research .
|
-
-
- HY-162230
-
|
Apoptosis
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-33 (compound A8) is a selective, SAM-competitve PRMT5 inhibitors with IC50 of 10.9 nM. PRMT5-IN-33 induces apoptosis and inhibits proliferation of cells Z-138 and MOLM-13. PRMT5-IN-33 exhibits an antitumor activity .
|
-
-
- HY-19615
-
|
Histone Methyltransferase
|
Cancer
|
MS023 is a potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50s of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively .
|
-
-
- HY-19615B
-
|
Histone Methyltransferase
|
Cancer
|
MS023 dihydrochloride is a potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50s of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively .
|
-
-
- HY-19615A
-
|
Histone Methyltransferase
|
Cancer
|
MS023 trihydrochloride is a potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50s of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively .
|
-
-
- HY-147185
-
|
Histone Methyltransferase
|
Cancer
|
PRMT7-IN-1 (Compound 14) is a PRMT7 inhibitor with an IC50 of 2.1 μM. PRMT7-IN-1 shows anticancer activity against different cancer cells .
|
-
-
- HY-141874
-
-
-
- HY-152236
-
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
PRMT6-IN-3 (compound 25) is a selective PRMT6 inhibitor with an IC50 value of 192 nM. PRMT6-IN-3 can induce apoptosis in cancer cells and has anticancer activity .
|
-
-
- HY-139823
-
-
-
- HY-144189
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-18 (Compound 002) is a potent PRMT5 inhibitor that can be used for the research of a disease mediated by PRMT5, such as cancer .
|
-
-
- HY-142211
-
-
-
- HY-149005
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-19 (Compound 41) is an selective orally active non-nucleoside PRMT5 inhibitor with IC50 values of 23.9 nM (radioactive biochemical assay) and 47 nM (AlphaLISA assay). PRMT5-IN-19 can occupy the SAM-binding pocket in PRMT5 and block methyltransferase activity, which displays good selectivity over other PRMTs and PKMTs. PRMT5-IN-19 inhibits cell proliferation by inducing cell apoptosis, and can be used for cancer-related research .
|
-
-
- HY-134883
-
-
-
- HY-141875
-
-
-
- HY-150081
-
-
-
- HY-139823A
-
|
Histone Methyltransferase
|
Others
|
PRMT5-IN-11 is a promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex in the (sub)micromolar range.
|
-
-
- HY-151576
-
|
Others
|
Cancer
|
PRMT5:MEP50 PPI is a novel PRMT5:MEP50 protein-protein interaction (PRMT5:MEP50 PPI) inhibitor, shows anti-tumor activity and anti-proliferative activity of lung and prostate cancer cells .
|
-
-
- HY-163434
-
|
EGFR
Histone Methyltransferase
|
Cancer
|
PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual PRMT5/EGFR inhibitor, with IC50s of 15.47 and 19.31 μM, respectively. PRMT5/EGFR-IN-1 exhibits antiproliferative activity against A549, MCF7, HeLa, and MDA-MB-231 cell lines. PRMT5/EGFR-IN-1 has favorable in vivo PK and PD properties. PRMT5/EGFR-IN-1 can significantly inhibit the growth of MCF7 orthotopic xenograft tumors .
|
-
-
- HY-132937
-
-
-
- HY-139611
-
|
Histone Methyltransferase
|
Cancer
|
MRTX-1719 is a potent, orally active, selective PRMT5•MTA complex inhibitor, with IC50 of 3.6 and 20.5 nM for PRMT5•MTA and PRMT5. MRTX-1719 binds to the PRMT5•MTA complex, with KD value of 0.14 pM. MRTX-1719 shows antineoplastic activity in vitro and in vivo, and can be used for cancer study .
|
-
-
- HY-12970A
-
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
EPZ020411 hydrochloride is a selective inhibitor of PRMT6 with an IC50 of 10 nM, it has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 hydrochloride can be used for the research of cancer .
|
-
-
- HY-12970
-
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
EPZ020411 is a selective inhibitor of PRMT6 with an IC50 of 10 nM, has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 can be used for the research of cancer .
|
-
-
- HY-144187
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-16 (Compound 20) is a PRMT5 inhibitor with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .
|
-
-
- HY-144188
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-17 (Compound 6) is a PRMT5 inhibitor with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .
|
-
-
- HY-111213
-
-
-
- HY-139611C
-
|
Histone Methyltransferase
|
Cancer
|
MRTX-1719 hydrochloride is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells .
|
-
-
- HY-141876
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-14 is a PRMT5 inhibitor to research cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
|
-
-
- HY-132309
-
BRD0639
1 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
BRD0639 is a first-in-class inhibitor of the PRMT5-substrate adaptor interaction. BRD0639 is a PRMT5 binding motif (PBM)-competitive agent that can support studies of PBM dependent PRMT5 activities .
|
-
-
- HY-126256
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5 IN-1, a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 11 nM for PRMT5/MEP50. PRMT5 IN-1 can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions .
|
-
-
- HY-P3822
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-23 (compound 50) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .
|
-
-
- HY-112165
-
-
-
- HY-126256A
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5 IN-1 hydrochloride (compound 9), a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 11 nM for PRMT5/MEP50. PRMT5 IN-1 hydrochloride can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions .
|
-
-
- HY-128717
-
EPZ019997
|
Histone Methyltransferase
|
Cancer
|
GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity .
|
-
-
- HY-128717A
-
EPZ019997 dihydrochloride
|
Histone Methyltransferase
|
Cancer
|
GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity .
|
-
-
- HY-128717B
-
EPZ019997 trihydrochloride
|
Histone Methyltransferase
|
Cancer
|
GSK3368715 trihydrochloride (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 trihydrochloride (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity .
|
-
-
- HY-124131
-
|
Histone Methyltransferase
|
Inflammation/Immunology
Cancer
|
DS-437 is a dual PRMT5/7 inhibitor (IC50s of PRMT5/7=6 μM). DS-437 is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. DS-437 is a S-adenosylmethionine (SAM)-competitive inhibitor of PRMT5. DS-437 also inhibits DNMT3A and DNMT3B, with IC50s of 52 and 62 μM, respectively. DS-437 inhibits the methylation of FOXP3 .
|
-
-
- HY-153390
-
|
Histone Methyltransferase
|
Cancer
|
AMG-193 (compound 481) is an inhibitor of PRMT5. PRMT5-IN-27 inhibits HCT116 cell proliferation with an IC 50 of 0.13 μM .
|
-
-
- HY-131493
-
PRMT5-IN-3
|
Histone Methyltransferase
|
Cancer
|
PF-06939999 (PRMT5-IN-3) is a PRMT5 inhibitor that exhibits synthetic lethality to tumor cells but produce few side effects combined with DNA damaging agents.
|
-
- HY-107777
-
LLY-283
2 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity.
|
-
- HY-138684
-
-
- HY-138684A
-
-
- HY-155814
-
-
- HY-120137
-
|
Histone Methyltransferase
|
Cancer
|
CMP-5 is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 prevents Epstein-Barr virus (EBV)-driven B-lymphocyte transformation but leaving normal B cells unaffected .
|
-
- HY-113846
-
|
Histone Methyltransferase
|
Cancer
|
CMP-5 hydrochloride is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 hydrochloride selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 hydrochloride prevents EBV-driven B-lymphocyte transformation but leaving normal B cells unaffected .
|
-
- HY-122096
-
DCLX069
1 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
DCLX069 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 value of 17.9 µM. DCLX069 shows less active against PRMT4 and PRMT6. DCLX069 has anticancer effects .
|
-
- HY-153421
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-28 (compound 36) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) enzyme. Protein arginine methylation is a common post-translational modification involved in gene transcription, mRNA splicing, DNA repair, protein cellular localization, cell fate determination and signal transduction, etc. Abnormal PRMT5 can promote cancer cell proliferation, resist apoptosis, enhance invasion and metastasis, and affect immune escape .
|
-
- HY-110137A
-
DB75; NSC 305831
|
Histone Methyltransferase
Phosphodiesterase (PDE)
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
Furamidine (DB75) is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 9.4 μM. Furamidine is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC50s of 166 µM, 283 µM, and >400 µM, respectively). Furamidine is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine is also an antiparasite agent .
|
-
- HY-110137
-
DB75 dihydrochloride; NSC 305831 dihydrochloride
|
Histone Methyltransferase
Phosphodiesterase (PDE)
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
Furamidine dihydrochloride (DB75 dihydrochloride) is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 9.4 μM. Furamidine dihydrochloride is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC50s of 166 µM, 283 µM, and >400 µM, respectively). Furamidine dihydrochloride is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine dihydrochloride is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine dihydrochloride is also an antiparasite agent .
|
-
- HY-141877
-
MS4322
1 Publications Verification
YS43-22
|
PROTACs
|
Cancer
|
MS4322 (YS43-22) is a first-in-class PRMT5 degrader and a valuable chemical tool (PROTAC) for exploring the PRMT5 functions in health and disease.
|
-
- HY-19714
-
XY1
1 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
XY1 is an analog of SGC707 (SGC707 is a potent, selective PRMT3 inhibitor with an IC50 value of 31 nM), but XY1 is completely inactive against PRMT3.
|
-
- HY-P1182
-
|
Histone Methyltransferase
|
Cancer
|
C21 is a potent, irreversible, and selective PRMT1 inhibitor with an IC50 of 1.8 μM. C21 inhibits PRMT6 with an IC50 of 8.8 μM .
|
-
- HY-RS11167
-
|
Small Interfering RNA (siRNA)
|
Others
|
PRMT1 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PRMT1 Human Pre-designed siRNA Set A
PRMT1 Human Pre-designed siRNA Set A
- HY-RS11168
-
|
Small Interfering RNA (siRNA)
|
Others
|
Prmt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt1 Mouse Pre-designed siRNA Set A
Prmt1 Mouse Pre-designed siRNA Set A
- HY-RS11169
-
|
Small Interfering RNA (siRNA)
|
Others
|
Prmt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt1 Rat Pre-designed siRNA Set A
Prmt1 Rat Pre-designed siRNA Set A
- HY-RS11170
-
|
Small Interfering RNA (siRNA)
|
Others
|
PRMT2 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PRMT2 Human Pre-designed siRNA Set A
PRMT2 Human Pre-designed siRNA Set A
- HY-RS11171
-
|
Small Interfering RNA (siRNA)
|
Others
|
PRMT3 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PRMT3 Human Pre-designed siRNA Set A
PRMT3 Human Pre-designed siRNA Set A
- HY-RS11172
-
|
Small Interfering RNA (siRNA)
|
Others
|
Prmt3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt3 Mouse Pre-designed siRNA Set A
Prmt3 Mouse Pre-designed siRNA Set A
- HY-RS11173
-
|
Small Interfering RNA (siRNA)
|
Others
|
Prmt3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt3 Rat Pre-designed siRNA Set A
Prmt3 Rat Pre-designed siRNA Set A
- HY-RS11174
-
|
Small Interfering RNA (siRNA)
|
Others
|
PRMT5 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PRMT5 Human Pre-designed siRNA Set A
PRMT5 Human Pre-designed siRNA Set A
- HY-RS11175
-
|
Small Interfering RNA (siRNA)
|
Others
|
Prmt5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt5 Mouse Pre-designed siRNA Set A
Prmt5 Mouse Pre-designed siRNA Set A
- HY-RS11176
-
|
Small Interfering RNA (siRNA)
|
Others
|
Prmt5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt5 Rat Pre-designed siRNA Set A
Prmt5 Rat Pre-designed siRNA Set A
- HY-RS11177
-
|
Small Interfering RNA (siRNA)
|
Others
|
PRMT6 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PRMT6 Human Pre-designed siRNA Set A
PRMT6 Human Pre-designed siRNA Set A
- HY-RS11178
-
|
Small Interfering RNA (siRNA)
|
Others
|
Prmt6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt6 Mouse Pre-designed siRNA Set A
Prmt6 Mouse Pre-designed siRNA Set A
- HY-RS11179
-
|
Small Interfering RNA (siRNA)
|
Others
|
PRMT6 Rat Pre-designed siRNA Set A contains three designed siRNAs for PRMT6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PRMT6 Rat Pre-designed siRNA Set A
PRMT6 Rat Pre-designed siRNA Set A
- HY-RS11180
-
|
Small Interfering RNA (siRNA)
|
Others
|
PRMT7 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PRMT7 Human Pre-designed siRNA Set A
PRMT7 Human Pre-designed siRNA Set A
- HY-RS11181
-
|
Small Interfering RNA (siRNA)
|
|
Prmt7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt7 Mouse Pre-designed siRNA Set A
Prmt7 Mouse Pre-designed siRNA Set A
- HY-RS11182
-
|
Small Interfering RNA (siRNA)
|
Others
|
Prmt7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt7 Rat Pre-designed siRNA Set A
Prmt7 Rat Pre-designed siRNA Set A
- HY-RS11183
-
|
Small Interfering RNA (siRNA)
|
Others
|
PRMT8 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PRMT8 Human Pre-designed siRNA Set A
PRMT8 Human Pre-designed siRNA Set A
- HY-RS11184
-
|
Small Interfering RNA (siRNA)
|
Others
|
Prmt8 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt8 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt8 Mouse Pre-designed siRNA Set A
Prmt8 Mouse Pre-designed siRNA Set A
- HY-RS11185
-
|
Small Interfering RNA (siRNA)
|
Others
|
Prmt8 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt8 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Prmt8 Rat Pre-designed siRNA Set A
Prmt8 Rat Pre-designed siRNA Set A
- HY-RS11186
-
|
Small Interfering RNA (siRNA)
|
Others
|
PRMT9 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PRMT9 Human Pre-designed siRNA Set A
PRMT9 Human Pre-designed siRNA Set A
- HY-100855
-
|
Histone Methyltransferase
|
Cancer
|
DC_C66 is a cell-permeable, selective coactivator associated arginine methyltransferase 1 (CARM1) inhibitor with an IC50 of 1.8 μM. DC_C66 has a good selectivity for CARM1 against PRMT1 (IC50=21 μM), PRMT6 (IC50= 47μM), and PRMT5 .
|
-
- HY-139611B
-
|
Histone Methyltransferase
|
Cancer
|
(S)-MRTX-1719 (example 16-7) is the S-enantiomer of MRTX-1719. (S)-MRTX-1719 is a PRMT5/MTA complex inhibitor, with an IC50 of 7070 nM .
|
-
- HY-100565
-
SGC2085
1 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
SGC2085 is a potent and selective inhibitor of coactivator associated arginine methyltransferase 1 (CARM1) with an IC50 of 50 nM. SGC2085 also selectively inhibits PRMT6 with an IC50 value of 5.2 μM, but not other PRMT proteins .
|
-
- HY-100565A
-
|
Histone Methyltransferase
|
|
SGC2085 hydrochloride is a potent and selective inhibitor of coactivator associated arginine methyltransferase 1 (CARM1) with an IC50 of 50 nM. SGC2085 hydrochloride also selectively inhibits PRMT6 with an IC50 value of 5.2 μM, but not other PRMT proteins .
|
-
- HY-110158
-
-
- HY-12727
-
-
- HY-128579
-
|
Histone Methyltransferase
|
Cancer
|
DW14800 is a protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 17 nM. DW14800 reduces H4R3me2s levels and enhances the transcription of HNF4α, but does not alter PRMT5 expression. Anti-cancer activity .
|
-
- HY-100025A
-
-
- HY-126300
-
-
- HY-100235
-
EPZ015866; GSK3203591
|
Histone Methyltransferase
|
Cancer
|
GSK591 (EPZ015866) is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC50 of 4 nM .
|
-
- HY-100235A
-
EPZ015866 hydrochloride; GSK3203591 hydrochloride
|
Histone Methyltransferase
|
Cancer
|
GSK591 (EPZ015866) hydrochloride is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC50 of 4 nM .
|
-
- HY-100360
-
|
Histone Methyltransferase
|
Cancer
|
MS049 is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC50s of 34 nM and 43 nM, respectively. MS049 reduces levels of Med12me2a and H3R2me2a in HEK293 cells. MS049 is not toxic and does not affect the growth of HEK293 cells .
|
-
- HY-100360A
-
|
Histone Methyltransferase
|
Cancer
|
MS049 dihydrochloride is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC50s of 34 nM and 43 nM, respectively. MS049 dihydrochloride reduces levels of Med12me2a and H3R2me2a in HEK293 cells. MS049 dihydrochloride is not toxic and does not affect the growth of HEK293 cells .
|
-
- HY-15890
-
-
- HY-112445
-
SGC3027
3 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
SGC3027 is a histone methyltransferase inhibitor . SGC3027 is the first potent, selective and cell active chemical probe for PRMT7 .
|
-
- HY-133740
-
|
Histone Methyltransferase
|
Cancer
|
MS117 is a first-in-class and cell-active irreversible protein arginine methyltransferase 6 (PRMT6) covalent inhibitor, with an IC50 of 18 nM .
|
-
- HY-156680
-
|
Histone Methyltransferase
|
Cancer
|
TNG-462 (Compound 1143) is an orally active PRMT5 inhibitor for investigation of MTAP-deficient and/or MTA-accumulating cancers .
|
-
- HY-114965
-
TP-064
2 Publications Verification
|
Histone Methyltransferase
|
Inflammation/Immunology
Cancer
|
TP-064 is a potent and selective proteinarginine methyltransferase 4 (PRMT4; CARM1) inhibitor (IC50 <10 nM). TP-064 inhibits dimethylation of BAF155 (IC50 of 340 nM) and MED12 (IC50 of 43 nM). TP-064 is inactive against the other family members except for PRMT6 (IC50 of 1.3 μM). TP-064 has anticancer activities .
|
-
- HY-19715
-
-
- HY-126300A
-
|
Histone Methyltransferase
|
Cancer
|
SGC6870N is inactive against PRMT6 and can be utilized as a negative control. SGC6870N is an inactive enantiomer of SGC6870 (HY-126300) .
|
-
- HY-148817
-
|
WDR5
|
Cancer
|
WDR5-0102 is an inhibitor targeting WDR5-MLL1 interface (Kdis=7 μM, Kd=4 μM). WDR5-0102 suppresses MLL1 HMT activity, but not human H3K4 methyltransferase SETD7 and six other HMTs: G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5 .
|
-
- HY-148419
-
|
Histone Methyltransferase
|
Cancer
|
TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research .
|
-
- HY-109963
-
-
- HY-107574
-
-
- HY-107777A
-
|
Others
|
Cancer
|
LLY-284 is the diastereomer of LLY-283 with much less active. LLY-283 is a potent inhibitor of PRMT5. LLY-284 has the potential for the research of cancer diseases .
|
-
- HY-101564
-
JNJ-64619178
|
Histone Methyltransferase
|
Cancer
|
Onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.14 nM. Onametostat has potent activity in lung cancer .
|
-
- HY-12759A
-
|
Histone Methyltransferase
|
Cancer
|
CARM1-IN-1 hydrochloride is a potent and specific CARM1 (Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7.
|
-
- HY-141877B
-
YS43-22 (isomer)
|
PROTACs
|
Cancer
|
MS4322 (YS43-22) isomer is an isomer of MS4322. MS4322 is a potent and selective PRMT5 (protein arginine methyltransferase 5) degrader, and inhibits growth of multiple cancer cell lines .
|
-
- HY-155051
-
|
Apoptosis
Histone Methyltransferase
|
Cancer
|
Antiproliferative agent-25 (Compound 3s4) is a selective PRMT5 inhibitor (IC50: 0.11 μM). Antiproliferative agent-25 up-regulates hnRNP E1 protein level. Antiproliferative agent-25 forms H-bond interactions with SAM and E444 residue of PRMT5. Antiproliferative agent-25 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. Antiproliferative agent-25 has high clearances with T1/2 of only 21.8 and 4.7 min in human and rat liver microsomes .
|
-
- HY-12759
-
|
Histone Methyltransferase
|
Cancer
|
CARM1-IN-1 is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM).
|
-
- HY-157151
-
|
Histone Methyltransferase
|
Cancer
|
iPRMT1 is a potent and selective PRMT1 inhibitor for breast cancer research. iPRMT1 inhibits breast cancer cell growth in vitro and in vivo with EC50 values of 90, 70, and 9 nM in MCF7, T47D, and MDA-MB-231 cells, respectively .
|
-
- HY-157388
-
|
Histone Methyltransferase
HDAC
|
Cancer
|
CARM1/HDAC2-IN-1 (compound CH-1) is a dual inhibitor against CARM1 and HDAC2, with IC50 values of 3.71 nM and 4.07 nM, respectively. CARM1/HDAC2-IN-1 possesses antitumor activity .
|
-
- HY-10929
-
UNC0224
1 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
UNC0224 is a potent and selective histone methyltransferase G9a inhibitor with a Ki of 2.6 nM, an IC50 of 15 nM and a Kd of 23 nM. UNC0224 also potently inhibits b>GLP with assay-dependent IC50 values of 20-58 nM. UNC0224 is inactive against SET7/9, SET8/PreSET7, PRMT3 and JMJD2E .
|
-
- HY-101563
-
GSK3326595
Maximum Cited Publications
15 Publications Verification
EPZ015938
|
Histone Methyltransferase
SARS-CoV
MDM-2/p53
CDK
Apoptosis
|
Infection
Cancer
|
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .
|
-
- HY-13807
-
UNC0646
1 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
UNC0646 is a potent and selective histone methyltransferase G9a inhibitor with an IC50 of 6 nM. UNC0646 is also a potent GLP inhibitor (IC50 <15 nM) and highly selective for G9a/GLP over SETD7, SUV39H2, SETD8 and PRMT3. UNC0646 reduces H3K9me2 levels in MDA-MB-231 cells with an IC50 of 26 nM .
|
-
- HY-161334
-
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
CARM1-IN-4 (compound 11f) is a potent CARM1 inhibitor with IC50s of 9 nM and 56 nM for CARM1 and PRMT1, respectively. CARM1-IN-4 displays significant anti-proliferative effects on colorectal cancer cell lines. CARM1-IN-4 effectively inhibits the methyltransferase activity of CARM1 and prevents methylation of downstream proteins. CARM1-IN-4 induces apoptosis and shows antitumor activity .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3822
-
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-23 (compound 50) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .
|
-
- HY-P1182
-
|
Histone Methyltransferase
|
Cancer
|
C21 is a potent, irreversible, and selective PRMT1 inhibitor with an IC50 of 1.8 μM. C21 inhibits PRMT6 with an IC50 of 8.8 μM .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: